SCHEMBL518987

SCHEMBL518987

C1=Cc2ncccc2SN1

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
ALOX15 P16050 1/20 0.30
MAPK10 P53779 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744209 0.73
Phenanthroline SCHEMBL21647822 0.71 LMNA (0.48) ALDH1A1ALOX15HSD17B10
SCHEMBL30381818 0.70
SCHEMBL4794238 0.69
SCHEMBL392669 0.69
SCHEMBL8129347 0.69
SCHEMBL5686105 0.67 PARP1 (0.34) ALOX15
Pyridine SCHEMBL28042502 0.66 TSHR (0.32)
SCHEMBL38654629 0.65 PARP1 (0.33) ALOX15
Fluoride SCHEMBL27762528 0.65 PARP1 (0.33) ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024246946-A1 NOVEL PYRIDINE CARBOXAMIDE COMPOUNDS WITH ANTI-TUBERCULAR ACTIVITY TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) 2024-12-05 WO claimed
CN-119072471-A Pyrazole substituted cyclopentyl ester derivative and application thereof 正大天晴药业集团股份有限公司 2024-12-03 CN claimed
EP-1586321-B1 New use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2008-12-10 EP claimed
EP-1586321-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2005-10-19 EP claimed
US-20050054619-A1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2005-03-10 US claimed
EP-0878196-B1 KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2003-09-03 EP claimed
US-6133258-A PYRIDOTHIAZINE DERIVATIVE; FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS, PAIN, GLAUCOMA YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2000-10-17 US claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP claimed
EP-0878196-A1 KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1998-11-18 EP claimed
WO-2024246946-A1 NOVEL PYRIDINE CARBOXAMIDE COMPOUNDS WITH ANTI-TUBERCULAR ACTIVITY TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) 2024-12-05 WO disclosed
CN-119072471-A Pyrazole substituted cyclopentyl ester derivative and application thereof 正大天晴药业集团股份有限公司 2024-12-03 CN disclosed
US-11786575-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-17 US disclosed
US-20220211802-A1 Endoparasitic Depsipeptides ZOETIS SERVICES LLC 2022-07-07 US disclosed
US-11331369-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2022-05-17 US disclosed
CN-1202109-A Kainic acid neuronotoxicity inhibitors and pyridothioazine derivatives YAMANOUCHI PHARMA CO LTD (JP) 1998-12-16 CN disclosed
EP-0878196-A1 KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1998-11-18 EP disclosed
EP-0878196-A1 KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1998-11-18 EP disclosed
US-5677300-A ALDOSE REDUCTASE INHIBITOR; USEFUL FOR TREATING OR PREVENTING THE COMPLICATIONS OF DIABETES, SUCH AS COTARACT AND NEUROSIS THE GREEN CROSS CORPORATION (JP) 1997-10-14 US disclosed
WO-1997017970-A1 KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-05-22 WO disclosed
EP-0644194-A1 PYRIDOTHIAZINEACETIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF THE GREEN CROSS CORPORATION (JP) 1995-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786575-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 ALDH1A1 3102/4885ALOX15 2013/4885MAPK10 4407/4885
US-20220211802-A1 Endoparasitic Depsipeptides VIP, PREP, NGLY1 ALDH1A1 3102/4885ALOX15 2013/4885MAPK10 4407/4885
US-11331369-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 ALDH1A1 3102/4885ALOX15 2013/4885MAPK10 4407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.